Current status and problems of perioperative complications of preoperative treatment for pancreatic head cancer

• Published in: Journal of Japan Society for Surgical Infection Vol. 16; no. 2; pp. 112 - 117
• Main Authors: Nakanishi, Yoshitsugu, Ebihara, Yuma, Asano, Toshimichi, Shichinohe, Toshiaki, Okamura, Keisuke, Noji, Takehiro, Hirano, Satoshi, Murakami, Soichi, Tanaka, Kimitaka, Nakamura, Toru, Tsuchikawa, Takahiro, Kurashima, Yo
• Format: Journal Article
• Language: Japanese
• Published: Japan Society for Surgical Infection 30.04.2019; 一般社団法人 日本外科感染症学会
• Subjects: SSI; 周術期合併症; 膵癌術前治療; 膵頭十二指腸切除
• ISSN: 1349-5755; 2434-0103
• DOI: 10.24679/gekakansen.16.2_112

In recent years, preoperative therapy for pancreatic cancer has been increasing. We retrospectively analyzed 184 consecutive patients with pancreatic head cancer during 2008-2018, 94 patients underwent upfront surgery and 90 patients received preoperative therapy. The rate of preoperative therapy was 72.3％ in last 5 years. The preoperative therapy group had lower age, high smoking rate, anemia, high platelet-lymphocyte ratio, long operative time, high blood transfusion rate, and high portal vein resection rate than upfront surgery group. There was no difference in postoperative complications including SSI, however, Clavien-Dindo Ⅳa was significantly higher in the preoperative therapy group (0.0％ vs 5.5％, P=0.02). In multivariate analysis, age . 68 years, operation time . 548 minutes, BMI . 21.5, and ALB ＜3.5g/dL were independent risk factors for SSI. Preoperative therapy was not a risk factor for SSI in pancreaticoduodenectomy.